Research programme: CD26 antigen antagonists - Ferring/Johnson And Johnson
Alternative Names: Dipeptidyl peptidase IV anatagonists - Ferring/Johnson And Johnson; DPP-IV antagonists - Ferring/Johnson And JohnsonLatest Information Update: 03 Mar 2008
At a glance
- Originator Ferring Pharmaceuticals
- Developer Ferring Pharmaceuticals; Johnson & Johnson
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Obesity
Most Recent Events
- 05 Nov 2002 Preclinical trials in Diabetes mellitus in USA (unspecified route)
- 05 Nov 2002 Preclinical trials in Obesity in USA (unspecified route)